Good morning, everyone, and thank you for participating in today's conference call to discuss Cardiff Lexington's financial results for the third quarter ended September 30, 2026. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. I will now turn the call over to Walter Frank. Please go ahead.
Thank you, operator. I would like to welcome everybody to the call. Hosting the call today are Cardiff Lexington's CEO, Alex Cunningham. Safe Harbor statement. This conference call contains forward-looking statements as defined within Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements and terms such as anticipate, expect, intend, may, will, should, or other comparable terms involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Those statements include statements regarding the intent, belief, or current expectations of Cardiff Lexington and members of its management, as well as the assumptions on which such statements are based.
Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, including those described in Cardiff Lexington's periodic reports filed with- From those contemplated by such forward-looking statements. Except as required by federal securities law, Cardiff Lexington undertakes no obligation to update or revise forward-looking statements to reflect changed conditions. I would now like to turn the call over to the CEO of Cardiff Lexington, Alex Cunningham.
Thank you, Walter. Good morning, and thank you for joining our conference call today to discuss our third quarter 2026 results. I'll start with an overview of our year-to-date performance and an update on our proposed acquisition before turning the call over to Matt Schaefer, our Chief Financial Officer, for a deeper dive into our financial results for the third quarter. We will then open the call for a brief question-and-answer period. Through the first nine months of 2026, we stayed focused on our long-term strategy of building Nova Ortho and Spine into a leading healthcare network and expanding access to high-quality care for a patient population that has long been underserved. Today, our network includes 11 Nova Ortho and Spine locations in both metropolitan and rural population centers across Florida and Georgia. Demand for our services remains strong.
However, working capital constraints have limited our ability to capitalize on opportunities. We remain focused on enhancing our access to working capital so that we can meet that demand and drive long-term sustainable shareholder value. During the quarter, we also took an important step in our growth strategy by announcing a letter of intent for a proposed acquisition of a leading musculoskeletal healthcare platform, which I will discuss in more detail in a moment. Financially, the year to date has been challenging. Revenue for the first nine months was $6.3 million compared with $8.8 million in the same period last year, primarily due to fewer procedures driven in part by working capital constraints and a lower implicit realization rate on patient case settlement claims, which was 40% as of September 2026, compared with 42% during the first nine months of 2025.
That said, we retained healthy gross margins of 56.2% of total revenue for the year to date. We recorded a non-GAAP Adjusted EBITDA loss of $292,000 compared with a non-GAAP Adjusted EBITDA of $1.9 million in the first nine months of 2025. We are confident that the strategic steps we are taking position us to drive improved operating performance. Turning to slide four. In September, we announced that we entered into a letter of intent for a proposed merger with an established multi-location healthcare platform serving patients in multiple states. We believe this represents a significant and critical opportunity for Cardiff Lexington. The business is highly complementary to Nova Ortho and Spine and brings a physician-led clinical organization and ancillary services such as diagnostic imaging and physical therapy, along with the potential for future ambulatory surgery center integration.
We structured the proposed transaction to include debt restructuring and refinancing, which will include significant new equity investors to address working capital shortfalls once and for all, while effectively merging as a long-term combination rather than simply an acquisition. The target acquisition has little to no appreciable debt and a very strong balance sheet. A substantial portion of the consideration would remain invested in Cardiff Lexington, and new much-needed investor equity would position current operations for growth and future acquisitions. The sellers, new investors, and the existing leadership team are expected to take on key management roles and board representation in the combined organization, aligning their interests with those of our shareholders. As for where things stand, we continue to make meaningful progress towards the execution of a definitive acquisition agreement. Due diligence and negotiations of definitive transaction documents remain ongoing.
We have received and accepted financing and equity term sheets and are actively advancing the related due diligence, underwriting, and documentation processes. While these additional steps have extended the previously anticipated November 16th timeline, we remain focused on completing the necessary requirements and advancing the transaction toward a definitive agreement, subject to satisfactory due diligence, final financing arrangements, and other customary conditions. We currently anticipate further progress in December, although no definitive execution date has been established. I would also note that the letter of intent is non-binding, other than certain provisions, and there can be no assurance that definitive agreements will be executed or that the transaction will be completed. Finally, we understand the stock has not performed well.
We believe this has been driven in part by dilution from conversions by convertible bridge loan note holders that increased our issued and outstanding shares by more than 2 million shares, as well as very high finance charges driving our net loss and negative Adjusted EBITDA. The management team and board are large shareholders and are very much aligned with our broader shareholder base. Something has to change, and we believe the best thing that we can do is to drive performance of the business and seek to remedy the undercapitalization driving perpetual working capital constraints. We believe this will translate into long-term shareholder returns. Demand for our services remains strong. We have a clear strategy in place, and the proposed acquisition, new equity, and debt refinancing package would create a larger, more integrated platform with a healthy balance sheet to sustain operations for the long term.
We have work ahead of us, but we are encouraged by where Cardiff Lexington is potentially headed. With that, I'll now hand the call over to our Chief Financial Officer, Matt Schaefer, to take a deeper dive into our financial results for the third quarter.
Thank you, Alex, and good morning, everyone. Thank you for joining us today. Turning to slide five. Total revenue for the third quarter of 2026 was $1.9 million, compared with revenue of $3.1 million in the same quarter last year. As Alex touched on briefly, the decline in revenue this quarter was primarily related to a lower realization rate on patient case claim settlements, as well as a decrease in procedures compared to the third quarter of 2025. Cost of sales was $875,000 in the third quarter of 2026, compared with approximately $1.1 million in the third quarter of 2025. Gross profit in the third quarter of 2026 was $1 million, or 54.2% of sales, compared to $1.9 million, or 62.4% of sales, in the third quarter of 2025.
Total operating expenses increased to $1.6 million, compared with $1.3 million in the third quarter of 2025, and included share-based compensation of $370,000, compared with $41,000 in the third quarter of 2025. Selling, general, and administrative expenses for the third quarter were $1.2 million, or 62.9% of revenue, compared with $1.2 million, or 40% of revenue, in the third quarter of 2025. Loss from continuing operations was $537,000 in the third quarter of 2026, compared with income from continuing operations of $643,000 in the third quarter of 2025. Shifting now to our profitability metrics. Net loss in the third quarter of 2026 totaled $3.2 million, compared with a net loss of $1.1 million in the third quarter of 2025. Included in net loss in the third quarter of 2026 was interest expense of $2.5 million, compared with interest expense of $1.8 million in the third quarter of 2025.
The increase in interest expense is primarily attributable to higher initial and incremental fees charged on existing purchases and claims under our line of credit, which, as Alex alluded to and as we've discussed on prior calls, reflects the higher-cost financing structures that we've used to fund our business as we continue to explore opportunities to increase our working capital. On a non-GAAP basis, we recognized an Adjusted EBITDA loss, which excludes interest expense, of $279,000 in the third quarter of 2026, compared with Adjusted EBITDA of $663,000 in the third quarter of 2025. A detailed reconciliation of Adjusted EBITDA to net income is provided in the press release issued earlier today. Moving now to the balance sheet. Our total assets as of September 30, 2026, were $30.6 million, compared to $29.1 million at December 31, 2025.
Current assets as of September 30, 2026, included $584,000 in cash and $23.4 million of net accounts receivable, while current assets at December 31, 2025, included $319,000 of cash and $22.1 million of net accounts receivable. Total liabilities as of September 30, 2026, were $29 million, compared to $26 million at December 31, 2025. With that, I will now turn the call back over to Alex.
Thanks, Matt. As we highlight on slide seven, in previous years, the Cardiff Lexington model has proven its ability to deliver strong returns on invested capital, even with limited access to working capital. Our priorities now are refinancing and securing the sustainable working capital necessary to restore that performance at a scale to build durable value for our shareholders. Patience and support, and we look forward to updating you on our progress. With that, operator, we are ready to open the call for questions.
Thank you. The floor is now open for questions. If you wish to join the queue to ask a question at this time, please press star one. We do ask if listening on speakerphone today, please pick up your handset while asking your question to provide optimal sound quality. Once again, please press star one on your phone at this time to join the queue to ask a question. Please hold a moment while we poll for questions. First question comes from Andrea Grieco with Stewart Capital. Please go ahead.
Hi. Thank you for taking my question. I was just wondering, as a result of this proposed acquisition, could Cardiff's existing shareholders end up owning a much smaller percentage of the company while new investors and sellers receive preferential treatment?
Andrea, this is Alex Cunningham, CEO. Thank you very much for your question. The short answer is yes, because the proposed transaction involves bringing in new equity, refinancing, and giving sellers significant equity in the company. Our existing shareholders will see their ownership percentage diluted, and those new investors will receive preferential rights. That's really just the cost of raising this kind of capital, merging with a much larger company. The real question isn't just about dilution, it's about whether this deal creates enough new value to make that trade-off worth it, and we truly believe it does. As we've noted in our SEC filings, securing new capital and managing our financial obligations are critical to just keep operations running smoothly. Right now, we're working hard to improve cash collections, manage expenses, and explore different financing options.
There are no guarantees those standalone efforts will be enough in the long term. When the board and management look at the final structure of this transaction, we are weighing everything together. The overall strength of the combined company, the current realities, the capital coming in, the preferential rights, the financing cost, and what truly benefits our shareholders. Our goal is to make sure existing shareholders can meaningfully share in the upside of a much larger, growing, and more financially stable healthcare organization. So at the end of the day, we believe long-term viability and real economic value creation, not simply ownership percentage, is the appropriate measure of whether the transaction benefits shareholders.
All right. Thank you. I think that's all I have for now.
Thank you for your question. Anybody else?
Thank you. At this time, I will turn the call back over to Alex Cunningham for any closing remarks.
Thank you. I appreciate everybody attending today, and we look forward to keeping our shareholders informed of developments. This is an active time, and we expect to be able to keep you informed in the near term and talk to you again in March. Have a great day.
Thank you. This does conclude today's conference call. You may disconnect your phone lines at this time, and have a wonderful day. Thank you for your participation.